文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

遏制中低收入国家HIV耐药上升:含多替拉韦方案的作用

Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
PubMed 文献 · Lancet Infect Dis · 2019-03-19

中低收入国家正从非核苷类逆转录酶抑制剂(NNRTI)转向多替拉韦以改善病毒学抑制并应对HIV耐药威胁。该转换可能降低NNRTI耐药影响并改善抗逆转录病毒治疗(ART)结局,但也带来育龄女性安全性担忧、预存核苷类逆转录酶抑制剂耐药可能降低多替拉韦有效性及耐久性、非B亚型多替拉韦耐药遗传相关数据不足、确认病毒学失败后临床管理困难等新挑战。

要点

  • 中低收入国家正从NNRTI转向含多替拉韦方案以改善病毒学抑制并应对HIV耐药。
  • 转换可能降低NNRTI耐药影响并改善ART结局,但存在育龄女性安全性等新挑战。
  • 预存核苷类逆转录酶抑制剂耐药可能降低多替拉韦有效性和耐久性。

核心结论

  • 中低收入国家广泛引入多替拉韦的预期获益需通过解决安全性、预存耐药、耐药遗传相关数据不足及病毒学失败管理等问题来巩固。

研究设计与样本

  • 本文为综述,讨论中低收入国家从NNRTI转向含多替拉韦ART的背景、预期获益与新挑战。

主要发现

  • 转向多替拉韦可能降低上升中的NNRTI耐药影响并改善ART结局。
  • 育龄女性使用多替拉韦的当前安全性担忧需要替代解决方案。
  • 对共同给药的核苷类逆转录酶抑制剂的预存耐药可能降低多替拉韦的有效性和耐久性,尤其在病毒载量检测可及性稀缺时。
  • 关于多替拉韦耐药的遗传相关因素信息不足,尤其在HIV-1非B亚型感染者中。
  • 含多替拉韦方案确认病毒学失败患者的临床管理存在挑战,因不确定多替拉韦耐药是否已发生及是否需要换药。

临床怎么用

  • 在中低收入国家推广含多替拉韦方案时,需关注育龄女性安全性、预存核苷类逆转录酶抑制剂耐药及病毒载量监测可及性。
  • 对含多替拉韦方案确认病毒学失败者,需判断多替拉韦耐药是否发生以决定换药或仅加强依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To improve virological suppression and address the emerging threat of HIV drug resistance, many low-income and middle-income countries are moving away from non-nucleoside reverse transcriptase inhibitors (NNRTI) and transitioning to dolutegravir as part of a more affordable and standardised antiretroviral therapy (ART). Although this transition could decrease the effect of rising NNRTI resistance and yield improved ART outcomes, it also presents new challenges. First, current safety concerns for dolutegravir use in women of childbearing potential require alternative solutions. Second, pre-existing resistance to the co-administered nucleoside reverse transcriptase inhibitors might reduce effectiveness and durability of dolutegravir, particularly if there is scarce access to viral load tests to monitor treatment outcomes. Third, there is inadequate information on the genetic correlates of resistance to dolutegravir, particularly in patients infected with HIV-1 non-B subtypes. Finally, clinical management of patients with confirmed virological failure on a dolutegravir-based regimen can pose challenges because of uncertainty around whether dolutegravir resistance has actually developed and switching is needed, or whether only interventions to improve adherence without switching are sufficient. These considerations should be addressed to consolidate expected gains from widespread introduction of dolutegravir in low-income and middle-income countries.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Inzaule SC, Hamers RL, Doherty M, et al. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019. PMID: 30902440. doi:10.1016/S1473-3099(18)30710-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。